LD-2 disclosure · 3rd Quarter - Report
APOTEX CORP.
via APOTEX CORP.
Client
- Name
- APOTEX CORP.
- Location
- Florida · United States of America
Registrant
- Firm
- APOTEX CORP.
- Description
- Generic pharmaceutical manufacturer
- Location
- WESTON, Florida, United States of America
Lobbying activities
2 issuesManufacturing
S. 4683, the National Defense Authorization Act for Fiscal Year 2025, Section 887, Requirement to produce domestically produced generic drugs, provisions relating to requiring the Department of Defense to purchase domestically manufactured generic drugs and use active pharmaceutical ingredients and key starting materials sourced domestically or from eligible countries; Federal policy relating to providing tax incentives to spur domestic manufacturing of generic drugs; and Federal policy related to Administration for Strategic Preparedness and Response initiatives to strengthen domestic pharmaceutical manufacturing capabilities.
LobbyistsSTEVEN GIULI
TargetedSENATE · Executive Office of the President (EOP) · Health & Human Services, Dept of (HHS)
Health Issues
Federal policy relating to addressing drug shortages and strengthening pharmaceutical supply chains through partnerships will North American and other allied countries; Draft Senate Finance Committee drug shortage legislation, provisions relating to Medicare reimbursement policies for generic drugs; Federal policy relating to the implementation of a pharmaceutical manufacturer reliability rating system and incentives in the Medicare program for providers to purchase generic drugs from manufacturers with higher reliability ratings;
LobbyistsSTEVEN GIULI
TargetedSENATE · Executive Office of the President (EOP) · Health & Human Services, Dept of (HHS)